TRMO

Across TCGA pan-cancer cohorts, TRMO RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated TRMO data layer compared with 3 for mutation status and 1 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher TRMO RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated TRMO expression acts as an unfavorable survival marker, although some lineages such as KIRC and KIRP show a favorable association.

KIRC, UVM, and ACC are the cancer types where TRMO RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Median	All	0.761	0.503	<.001	119	view →
UVM	DFS	Median	III,IV	0.270	0.707	.004	50	view →
ACC	DFS	Quartile	All	0.232	0.800	<.001	46	view →
KIRP	DFS	Median	All	1.000	0.794	.002	26	view →
LGG	DFS	Median	All	0.877	0.785	<.001	25	view →
SKCM	DFS	Tertile	All	0.309	0.129	.005	23	view →
COAD	OS	Median	IV	0.270	0.713	.001	23	view →
CHOL	OS	Median	II,III,IV	0.763	0.318	.024	21	view →
SCLC	DFS	Quartile	II,III,IV	0.707	0.253	.001	21	view →
MESO	DFS	Tertile	IV	0.277	0.785	.002	21	view →
LIHC	DFS	Quartile	All	0.439	0.608	.002	18	view →
UCEC	DFS	Median	All	0.928	0.867	.008	18	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 20 lineages.

TRMO–KIRC (DFS)

Open the KIRC breakdown →